IRRAS AB publishes Interim Report for the period January to September 2019
IRRAflow Gaining Traction in US ” Since the US is the world’s largest market for neurosurgical procedures, we have focused much of our team’s resources toward supporting a successful early market introduction. Response to our IRRAflow technology remains strong, and our sales funnel is full. Patient treatments with IRRAflow continued to increase, and multiple hospital systems moved from evaluating IRRAflow into the approval and purchasing phase.” Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS Third quarter, July – September 2019 · Net revenue amounted to SEK